Bioptimus is building the first universal AI foundation model that connects biology at its different scales – from molecules to cells, tissues, and whole organisms. The company trains foundation models natively across modalities and scales to learn the dynamics of human biology and predict what happens next.
Its models are designed to jointly learn from multimodal data spanning histology, spatial transcriptomics, genomics, and clinical records. This enables deeper biological insights for drug discovery, biomarker identification, indication expansion, and clinical trial design.
Bioptimus powers research at over 1,000 institutions worldwide, including 16 of the top 20 pharma companies. Its models are benchmarked as the #1 performing in independent evaluations and are used in peer-reviewed research and real-world applications.
The company is driven by a world-class team with deep expertise in machine learning and biology, originating from institutions like Google Brain, Google DeepMind, MIT, ETH Zürich, and more. 60% of the team hold PhDs, and it is guided by a scientific advisory board at the frontier of AI and biology.
